López-Jiménez J, Sánchez A, Fernández C S, Gutiérrez C, Herrera P, Odriozola J
Department of Haematology, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain.
Bone Marrow Transplant. 1997 Aug;20(3):243-5. doi: 10.1038/sj.bmt.1700878.
We report the case of a BMT recipient who developed blindness 22 months after BMT. Microvascular retinopathy, cortical blindness and other ocular pathologies were excluded with appropriate tests. Electrophysiological studies showed retinal damage without excluding an optic nerve lesion. The patient, who had several risk factors for neurologic-induced cyclosporine toxicity, improved with cyclosporine withdrawal. Our findings stress the need of electrophysiological tests to exclude neuroretinal damage in patients receiving cyclosporine after BMT.
